Skip to content
Screener

Repligen RGEN Acquisition Date Fair Value Of Contingent Consideration Earnouts

Acquisition Date Fair Value Of Contingent Consideration Earnouts at other companies

Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$0-100%
Playtika Holding Corp. logo
Playtika Holding Corp.PLTK
$1.98M
Playtika Holding Corp. logo
Playtika Holding Corp.PLTK
$1.98M
Playtika Holding Corp. logo
Playtika Holding Corp.PLTK
$1.98M
Playtika Holding Corp. logo
Playtika Holding Corp.PLTK
$1.98M
ConocoPhillips logo
ConocoPhillipsCOP
$0

Other financials

Income statement

See full
Revenue$204.1M+11.9%
Gross profit$110.0M+20.7%
Operating income$14.0M+0.6%
Net income$5.0M-66.3%
EPS (diluted)$0.09-65.4%

Balance sheet

See full
Cash & equivalents$606.8M-14.4%
Total debt$690.9M+354%
Total equity$2.1B+2.4%
Total assets$3.0B+1.7%

Cash flow

See full
Operating cash flow$32.8M+14.5%
CapEx$5.3M-24.9%
Free cash flow$27.4M+27.5%

Valuation

See full
Market cap$9B+42.9%
Enterprise value$9.08B+58.2%
P/E216.6×
P/S11.7×+0.3×

Profitability

See full
Gross margin47.6%+0.9pp
Operating margin15.6%-11.0pp
Net margin17.3%-3.5pp
FCF margin22%+6.9pp

Returns & leverage

See full
Return on equity2%+1.6pp
Debt / equity0.3×+0.3×
Current ratio9.1×+0.5×

Where this comes from

Reported directly by Repligen in its filing.

Tagged under the XBRL concept rgen:AcquisitionDateFairValueOfContingentConsiderationEarnouts.

The source filing: Repligen’s 10-K, filed February 26, 2026.

Filed
Feb 26, 2026, 4:03 PM EST
Fiscal year
FY2025
Accession
0001193125-26-076528
Line itemYear Ended December 31, 2025Year Ended December 31, 2024Year Ended December 31, 2023
Cash and cash equivalents, end of period$566,021$757,355$751,323
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases$5,352$37,894$4,335
Fair value of shares of common stock issued for acquisitions$13,569
Fair value of shares of common stock issued for contingent consideration earnouts$7,568$5,742$7,229
Acquisition date fair value of contingent consideration earnouts$19,738$6,640
Issuance of 2023 Notes in exchange of 2019 Notes$42,179
Extinguished 2019 Notes$29,634

ITEM 16. 10-K SUMMARY

FAQ

What is Repligen's acquisition date fair value of contingent consideration earnouts?
Repligen (RGEN) reported acquisition date fair value of contingent consideration earnouts of $0 in Q4 2025.
How has Repligen's acquisition date fair value of contingent consideration earnouts changed year-over-year?
Repligen's acquisition date fair value of contingent consideration earnouts decreased by 100.0% year-over-year, from $4.93M to $0.
What is the long-term trend for Repligen's acquisition date fair value of contingent consideration earnouts?
Over 4 years (2021 to 2025), Repligen's acquisition date fair value of contingent consideration earnouts has grown at a -100.0% compound annual growth rate (CAGR), from $88.37M to $0.
What does acquisition date fair value of contingent consideration earnouts mean?
This metric quantifies the initial estimated value of future performance-based payments promised to sellers at the time of an acquisition. It serves as a baseline for understanding the total potential purchase price and the risk profile of the acquired assets. It helps investors assess the company's aggressive or conservative approach to inorganic growth.

Ask your AI about Repligen's acquisition date fair value of contingent consideration earnouts.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude